861 related articles for article (PubMed ID: 12566300)
1. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
[TBL] [Abstract][Full Text] [Related]
2. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Yao M; Zhou W; Sangha S; Albert A; Chang AJ; Liu TC; Wolfe MM
Clin Cancer Res; 2005 Feb; 11(4):1618-28. PubMed ID: 15746067
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
[TBL] [Abstract][Full Text] [Related]
4. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M
Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
6. Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
Becerra CR; Frenkel EP; Ashfaq R; Gaynor RB
Int J Cancer; 2003 Jul; 105(6):868-72. PubMed ID: 12767075
[TBL] [Abstract][Full Text] [Related]
7. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.
Fenwick SW; Toogood GJ; Lodge JP; Hull MA
Gastroenterology; 2003 Sep; 125(3):716-29. PubMed ID: 12949718
[TBL] [Abstract][Full Text] [Related]
8. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer.
Evans JF
Am J Clin Oncol; 2003 Aug; 26(4):S62-5. PubMed ID: 12902858
[TBL] [Abstract][Full Text] [Related]
9. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.
Swan SK; Rudy DW; Lasseter KC; Ryan CF; Buechel KL; Lambrecht LJ; Pinto MB; Dilzer SC; Obrda O; Sundblad KJ; Gumbs CP; Ebel DL; Quan H; Larson PJ; Schwartz JI; Musliner TA; Gertz BJ; Brater DC; Yao SL
Ann Intern Med; 2000 Jul; 133(1):1-9. PubMed ID: 10877734
[TBL] [Abstract][Full Text] [Related]
10. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer.
Yao M; Lam EC; Kelly CR; Zhou W; Wolfe MM
Br J Cancer; 2004 Feb; 90(3):712-9. PubMed ID: 14760389
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury.
Tanaka A; Araki H; Hase S; Komoike Y; Takeuchi K
Aliment Pharmacol Ther; 2002 Apr; 16 Suppl 2():90-101. PubMed ID: 11966529
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.
Richter M; Weiss M; Weinberger I; Fürstenberger G; Marian B
Carcinogenesis; 2001 Jan; 22(1):17-25. PubMed ID: 11159736
[TBL] [Abstract][Full Text] [Related]
15. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
Crew TE; Elder DJ; Paraskeva C
Carcinogenesis; 2000 Jan; 21(1):69-77. PubMed ID: 10607736
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-inflammatory activity of omega-3 lipid and rofecoxib pretreatment on macrophage proinflammatory cytokine production occurs via divergent NF-kappaB activation.
Babcock TA; Helton WS; Anwar KN; Zhao YY; Espat NJ
JPEN J Parenter Enteral Nutr; 2004; 28(4):232-9; discussion 239-40. PubMed ID: 15291404
[TBL] [Abstract][Full Text] [Related]
17. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2: a novel target for cancer chemotherapy?
Dempke W; Rie C; Grothey A; Schmoll HJ
J Cancer Res Clin Oncol; 2001 Jul; 127(7):411-7. PubMed ID: 11469677
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage.
Tanaka A; Hase S; Miyazawa T; Takeuchi K
J Pharmacol Exp Ther; 2002 Mar; 300(3):754-61. PubMed ID: 11861778
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
